Kyalin Biosciences, Retrophin, Novartis deal

Retrophin entered into two separate deals for oxytocin-based products to develop into treatments for autism and schizophrenia. Retrophin will acquire Kyalin for an undisclosed amount. Kyalin's most advanced product is an intranasal delivery form of carbetocin, a synthetic analog of oxytocin that was in development for autism. Kyalin founder and President Srinivas Rao joined Retrophin as EVP, head of neuroscience. The deal is to close this month. Retrophin and Kyalin could not be reached for comment. ...